PATENT CLAIM ANALYSIS

Application Number: 16143523
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-05
Patent Classification: ["546", "184000"]

Abstract:
This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

Claim (Index 19):
The method of  claim 15 , wherein the neuropathic pain is due to multiple sclerosis.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 97.0
- Lexical Diversity: 1.22222
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15491035', '14278064', '14891051', '13141105', '13238054']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7580040437439285
- 35 USC 102 Novelty (BERT): 0.4906363840045707
- Combined Prediction Score: 0.7312672777699927
- Mean Citation Score: 214.12837800000003
- Max Citation Score: 233.28214
- Similarity Product: 188.4372050733137

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test